Neurocrine Bioscienes supports Tardive Dyskinesia Awareness Week

TD is a persistent, involuntary movement disorder associated with the use of antipsychotic medication that may be necessary to treat individuals living with mental illness, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder. For seven consecutive years, TD Awareness Week – which occurs each year during Mental Health Awareness Month – has brought together the mental health advocacy community and states across the country to recognize the approximately 600,000 people in the U.S. living with TD. This year, Neurocrine is joining participants of TD Awareness Week to conduct initiatives nationwide to decrease stigma, improve recognition and increase routine screenings, diagnosis and awareness of appropriate treatment of TD.As part of its support for the week-long awareness push, Neurocrine directed patients and doctors to its many resources devoted to the disorder: The TD Awareness page on Neurocrine’s website and the standalone site for its long-running “Talk About TD” campaign both offer a range of information to educate patients and their caregivers and loved ones about the condition and guide their conversations about it, while Neurocrine’s faculty-led MIND-TD site is aimed at providing doctors with clinical data and guidance around recognizing, diagnosing and treating TD.